自主研发筑基，BD 合源，双轮驱动创新价值高效兑现 ——迈威生物深度报告 迈威生物-U（688062.SH） 化学制药 证券研究报告/公司深度报告 2026 年 02 月 25 日 | 公司盈利预测及估值 | | | | | | | --- | --- | --- | --- | --- | --- | | 指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | 营业收入（百万元） | 128 | 200 | 674 | 1,163 | 1,273 | | 增长率 yoy% | 361% | 56% | 238% | 72% | 10% | | 归母净利润（百万元） | -1,053 | -1,044 | -922 | -661 | -355 | | 增长率 yoy% | -10% | 1% | 12% | 28% | 46% | | 每股收益（元） | -2.64 | -2.61 | -2.31 | -1.65 | -0.89 | | 每股现金流量 | -1.96 | -2.39 | -1.81 | -1.29 | 0.17 | | 净资产收益率 | -40% | -6 ...

Core Insights - The 44th J.P. Morgan Healthcare Conference highlighted the global pharmaceutical industry's focus on innovation and the search for next-generation pipelines, with HengRui Pharma presenting its global strategy and capabilities [1][2]. Group 1: Company Strategy and Development - HengRui Pharma has established a "dual-engine" model, investing over 25% of its annual revenue in R&D, which supports its position as the second-largest in global original drug pipelines [2]. - The company is advancing its internationalization through flexible BD collaborations and a solid overseas team, aiming to accelerate the realization of innovative value [2][3]. - HengRui's R&D framework includes over 100 new molecular entities (NMEs) and more than 400 clinical trials across key therapeutic areas such as oncology, cardiovascular, metabolism, immunology, and neuroscience [3][7]. Group 2: Innovation and Pipeline - HengRui's pipeline is structured to provide comprehensive solutions in critical disease areas, focusing on synergy, iterative innovation, and addressing unmet medical needs [7]. - The company has demonstrated breakthrough capabilities in challenging targets, such as the KRAS G12D inhibitor HRS-4642, which has shown a 63.3% objective response rate in clinical trials [8]. - In the metabolic disease sector, HengRui is targeting the $100 billion obesity market with its GLP-1 asset portfolio, including the dual agonist HRS9531, which has shown significant weight loss results in clinical trials [8]. Group 3: Business Development and Internationalization - Since 2023, HengRui has completed 12 licensing deals worth over $27 billion, securing $1.3 billion in cash and equity investments, showcasing its R&D strength and innovation quality [12]. - The company aims to push approximately 20 new molecular entities into clinical trials annually, indicating a robust and efficient R&D pipeline [9][12]. - HengRui's internationalization strategy includes establishing a global capability system, with 15 R&D centers and a team of over 5,600, enhancing its global presence and operational capacity [13]. Group 4: Future Outlook - In 2026, HengRui is expected to achieve significant milestones, including over 10 new drug approvals and more than 20 NDA/BLA submissions, with key data from its pipeline assets anticipated [14]. - The company projects a revenue growth of over 25% year-on-year from its innovative drugs, supported by new products entering the national medical insurance directory [15]. - HengRui is committed to becoming a global leader in pharmaceuticals, focusing on delivering innovative drugs to patients worldwide, reflecting the broader trend of Chinese innovation in the pharmaceutical industry [16].

Core Viewpoint - The company is actively pursuing business development (BD) opportunities and diversifying its product pipeline, while facing various uncertainties in achieving these collaborations [2]. Group 1: Company Performance - As of December 23, 2025, the company's stock price closed at 93.69 yuan, down 1.58%, with a turnover rate of 1.35%, a trading volume of 54,000 shares, and a transaction amount of 508 million yuan [1]. Group 2: Business Development (BD) Efforts - The company is committed to enhancing its intrinsic value and promoting high-quality development through BD collaborations, although the success of these efforts is subject to multiple uncertainties [2]. - The company has ongoing discussions regarding potential BD projects, but specific details will be disclosed only when they meet legal disclosure standards [2]. - The company is focused on leveraging its strengths in brand, channels, and quality to adapt to regulatory requirements and enhance product sales [2]. Group 3: Market and Investor Relations - On December 23, there was a net outflow of 80.74 million yuan from institutional investors, while retail investors saw a net inflow of 48.95 million yuan [3][4]. - The company emphasizes the importance of investor relations and is utilizing various communication methods to maintain close contact with investors [2].

Core Viewpoint - Changchun High-tech (000661) is committed to enhancing its intrinsic value to drive high-quality development and is actively pursuing BD cooperation and diversification transformation [1] Group 1 - The company emphasizes its dedication to high-quality development through intrinsic value enhancement [1] - Ongoing efforts are being made to advance BD cooperation matters [1] - The company will fulfill disclosure obligations in accordance with legal regulations when relevant information reaches disclosure standards [1]

Core Insights - The pharmaceutical industry has seen a significant increase in merger and acquisition (M&A) activities since 2025, with 64 disclosed M&A events in A-shares, totaling approximately 110.38 billion yuan [1] - The trend indicates a dual-driven strategy of M&A and business development (BD) collaborations, focusing on enhancing innovation and filling gaps in capabilities [1][3] - The primary focus of M&A activities is on innovative drug research and development, medical services, and medical devices, reflecting a shift towards high-value sectors [1][2] M&A Trends - Pharmaceutical companies are increasingly acquiring near-commercial or mature technology platforms as a shortcut to catch up with technological advancements and address R&D shortcomings [2] - Notable M&A examples include Shijiazhuang Pharmaceutical's acquisition of a 29% stake in a biotech firm for 1.1 billion yuan and China Biologic's planned acquisition of 95.09% of a Shanghai-based company for 951 million USD [2] BD Collaborations - BD collaborations are also crucial for supplementing innovative drug pipelines, as seen in Changchun High-tech's partnership with ALK for allergy immunotherapy products [3] - Experts indicate that the current M&A and BD collaboration landscape is reshaping the industry, with a focus on building barriers in cutting-edge technologies like dual antibodies and ADCs [3] Industry Integration - The pharmaceutical industry is undergoing deeper integration, aiming to create a comprehensive closed-loop system encompassing R&D, production, and sales [4] - External collaborative M&A is a key pathway to achieving this closed-loop, as demonstrated by Chengdu Kanghua's acquisition aimed at enhancing its vaccine ecosystem [4] Capital Dynamics - The M&A landscape in 2025 is characterized by a multi-faceted capital structure, with leading companies taking the lead, supported by industry funds and flexible participation from social capital [6] - Leading firms are playing a stabilizing role, as seen in Beijing Tiantan's acquisition to enhance its plasma collection capabilities [6] Investment Strategies - Industry funds are exploring a "capital + BD" light asset model, with companies like Shanghai Fosun investing in innovative drug and medical device sectors [7] - Social capital is adopting a structured investment approach to empower innovation, focusing on AI medical applications and innovative drugs [7] Future Outlook - There is an expectation of continued capital investment in gene therapy, ADCs, and dual antibody platforms, indicating a sustained focus on high-value innovation areas [8]

Investment Rating - The report maintains an investment rating of "Buy" for the company with a target price of HKD 12.75 [7]. Core Views - The company achieved a revenue of RMB 19.89 billion for the first three quarters of 2025, representing a year-over-year decline of 12.3%, but a growth of 3.4% year-over-year in Q3 [1]. - The net profit attributable to the parent company for the first three quarters was RMB 3.51 billion, down 7.1% year-over-year, with Q3 profit showing a significant increase of 27% year-over-year [1]. - The revenue growth in Q3 is attributed to the narrowing decline in the prescription drug business and the gradual dissipation of the impact from centralized procurement [1][2]. - The company is optimistic about the continued market expansion of new products such as Omaguzumab and Mingfule under the backdrop of ongoing market development [1][2]. Summary by Sections Revenue and Profitability - The company reported a revenue of RMB 19.89 billion for 1-3Q25, with Q3 revenue showing a 3.4% year-over-year increase and a 5.7% quarter-over-quarter increase [1]. - The net profit for 1-3Q25 was RMB 3.51 billion, with Q3 profit at RMB 960 million, indicating a strong recovery in profitability [1]. Product Pipeline and Business Development - The report highlights the potential of the EGFR ADC pipeline, with ongoing clinical trials both domestically and internationally, indicating strong competitive advantages [3]. - The company confirmed BD revenue of RMB 1.54 billion in 1-3Q25, with expectations for continued BD opportunities in 2026 [4]. Future Outlook - The company anticipates a return to positive growth in prescription drug revenue by 2026, driven by new product launches and the absence of major products in the latest round of centralized procurement [2]. - The projected net profits for 2025-2027 are RMB 4.55 billion, RMB 4.63 billion, and RMB 5.03 billion respectively, with corresponding EPS estimates of RMB 0.40, RMB 0.40, and RMB 0.44 [5][10].

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 56.44 CNY, indicating a potential upside from the current price of 47.48 CNY [3][6]. Core Insights - The company has shown significant revenue growth, with a 301.0% increase in revenue for the first three quarters of 2025, amounting to 5.66 billion CNY. The net profit attributable to the parent company was -5.98 billion CNY, reflecting a 13.9% year-on-year improvement [10]. - The report highlights successful clinical advancements and commercialization efforts, with multiple new clinical trials set to commence and ongoing collaborations expected to enhance revenue streams [10]. - The financial forecasts have been adjusted, with a downward revision for 2025 revenue and R&D expenses, while 2026 revenue and management expenses have been increased. The projected net profits for 2025-2027 are -7.35 billion CNY, -6.55 billion CNY, and -2.91 billion CNY respectively [3][10]. Financial Summary - Revenue projections for 2025 are set at 747 million CNY, with a year-on-year growth of 274.1%. By 2026, revenue is expected to reach 1.066 billion CNY, growing at 42.6% [5]. - The company is expected to incur a net loss of 735 million CNY in 2025, improving to a loss of 655 million CNY in 2026, and further narrowing to 291 million CNY by 2027 [5]. - The gross margin is projected to be 93.5% in 2025, with a net margin of -98.4% [5]. - The company’s market capitalization is estimated at 225.55 billion CNY based on discounted cash flow valuation [11].

Core Viewpoint - The article highlights the accelerated pace of Chinese innovative pharmaceuticals entering international markets, with a comprehensive recovery in the healthcare industry observed in both primary and secondary markets this year [1]. Group 1: Market Dynamics - Overseas investors are showing a steady increase in interest towards Chinese healthcare companies, with more institutions willing to participate as cornerstone investors in Hong Kong IPOs [2][6]. - The capital market is experiencing a revival, with frequent financing activities and an increase in out-licensing projects, providing strong support for industry development [6][10]. - In the first half of the year, there were 677 financing transactions in the domestic healthcare primary market, totaling over 50 billion yuan, a year-on-year increase of 10% [6]. Group 2: Investment Trends - Investment focus is shifting from financial metrics to technological innovation capabilities, particularly in innovative drugs, medical devices, and artificial intelligence [6][10]. - The return of global funds is partly driven by the successful IPO of Ningde Times and the strong performance of companies like Hengrui Medicine, which has boosted investor confidence [7][10]. Group 3: Challenges in International Expansion - Chinese innovative pharmaceutical companies face challenges in their international expansion, including the risk of collaboration termination and regulatory hurdles, particularly in adapting to FDA requirements [8][10]. - Intellectual property issues are also critical, as some transactions have failed due to IP concerns [8]. Group 4: Enhanced Bargaining Power - Chinese pharmaceutical companies have significantly improved their bargaining power in the global value chain, with international collaborations expanding in breadth and depth [10]. - This enhanced bargaining power is reflected in improved deal terms, including higher upfront payments and more diverse transaction models [10]. Group 5: Future Outlook - The investment and financing activity in the healthcare sector is expected to continue, supported by the ongoing development of the industry and the increasing value of international investment banks' services [11][12]. - The trend of overseas funding returning is still in its early stages, with potential for further liquidity improvements [12]. - The industry is moving towards maturity and globalization, with a growing number of local companies transitioning from followers to key players on the global stage [13].

Investment Rating - The report maintains a positive outlook on the innovative drug sector and suggests focusing on quality defensive assets in the pharmacy sector [1][11]. Core Views - The innovative drug industry continues to show long-term potential, with Chinese pharmaceutical companies demonstrating their strength in international markets. The report anticipates further business development (BD) activities from domestic companies [2][37]. - In the pharmacy sector, leading companies are expected to enhance their market share through mergers and acquisitions, supported by strong cash flow and self-sustaining capabilities. The report highlights the defensive attributes of these leading pharmacies [2][47]. - The report emphasizes the importance of monitoring the updates to the essential drug list and identifies companies with potential for inclusion, such as Fangsheng Pharmaceutical [2][11]. Summary by Sections Innovative Drugs - The report highlights a significant global strategic partnership between Innovent Biologics and Takeda, involving three second-generation IO and ADC products, with a total transaction value potentially reaching $11.4 billion [2][37]. - It suggests focusing on dual/multi-antibody drugs and slow disease medications that meet unmet clinical needs, as well as ADC and small nucleic acid therapies [11]. Pharmacies - The report notes that the retail scale of physical pharmacies in China reached 50.4 billion yuan in August 2025, indicating a recovery trend despite a slight year-on-year decline [2][42]. - Leading pharmacy chains are expected to increase their market share during the industry clearing phase, with a focus on mergers and acquisitions when the timing is right [2][47]. Traditional Chinese Medicine - The report advises paying attention to the progress of the essential drug list updates and highlights companies like Huazhong Sanjiu that have already absorbed high baseline pressures [2][11]. Biopharmaceuticals - The report discusses the promising results of the ASO drug Bepirovirsen for hepatitis B treatment, suggesting continued monitoring of research developments in this area [3][11]. Medical Devices - The report indicates that leading companies are accelerating their international strategies, with successful product registrations in markets like Ecuador [3][11]. Medical Services and Consumer Healthcare - The report notes a year-on-year increase in total medical visits in Chongqing, suggesting a recovery in the medical services sector [3][11].

Core Viewpoint - The company reported a decline in revenue and net profit for the first half of 2025, primarily due to the impact of centralized procurement on its core oncology products and a decrease in sales from the pharmaceutical segment [1][2]. Financial Performance - In the first half of 2025, the company's revenue decreased by 18.5% year-on-year to 13.27 billion yuan, while net profit attributable to shareholders fell by 15.6% to 2.55 billion yuan, aligning with expectations [1]. - The overall gross margin declined by 6.0 percentage points to 65.6%, with the pharmaceutical segment's sales contribution dropping from 83.2% in the previous year to 77.2% [1]. - The sales expense ratio decreased by 6.4 percentage points to 23.0% [1]. Pharmaceutical Segment Performance - The pharmaceutical segment's sales fell by 24.4% year-on-year to 10.25 billion yuan, including licensing fee income of 1.08 billion yuan [2]. - Sales of oncology products dropped by 60.8% to 1.05 billion yuan, accounting for 10.3% of the pharmaceutical segment's revenue, due to price reductions from centralized procurement [2]. - Sales of products for neurological diseases decreased by 28.3% due to price cuts on Enbrel [2]. - The raw materials business saw a revenue increase of 21.6% to 1.20 billion yuan, driven by higher overseas demand, while antibiotic raw materials revenue remained stable with a 0.9% increase to 879 million yuan [2]. - Revenue from functional foods and other businesses grew by 8.0% to 951 million yuan, mainly due to increased sales volume [2]. Business Development Opportunities - The company has achieved multiple business development (BD) collaborations, with four external licensing agreements since February 2025, totaling upfront payments of 260 million USD and milestone payments of 9.45 billion USD [2]. - Potential BD transactions are in communication with partners, with a total consideration of approximately 5 billion USD for each transaction [2]. - The company announced a BD collaboration with AstraZeneca in June 2025 and expects to finalize two additional transactions in the second half of the year [2]. R&D Progress - R&D expenses increased by 5.5% year-on-year to 2.68 billion yuan, with the R&D expense ratio rising by 4.6 percentage points to 20.2% [3]. - The company has 27 core pipeline products in critical II/III clinical phases, covering both oncology and non-oncology areas, including 11 biopharmaceuticals and 10 chemical drugs [3]. - The core ADC pipeline, SYS6010 (EGFR ADC), is under development for multiple indications, with ongoing clinical trials for various NSCLC types [3].